Chemical inhibitors of ATP-binding cassette, sub-family A member 8a (ABCA8a) provide a spectrum of inhibition mechanisms targeting different functional domains of the protein. Verapamil, for example, blocks the ATP-binding sites critical for the ATPase activity of ABCA8a, which is essential for the energy-dependent transport of substrates across cellular membranes. Similarly, Quercetin impairs the ATPase activity by directly interacting with the ATP-binding domains, thereby halting the translocation process. Another inhibitor, Elacridar, binds to the transmembrane domains of ABCA8a, which are crucial for substrate recognition, thus preventing the substrate from being transported. Tariquidar and Zosuquidar exert their inhibitory action through a non-competitive antagonism by binding to allosteric sites and nucleotide-binding domains, respectively, altering the protein's conformation and inhibiting the ATP hydrolysis step.
Protein conformation and ATP hydrolysis are further targeted by inhibitors such as Laniquidar, which interferes with the substrate translocation process by engaging the transmembrane domains of ABCA8a. Reserpine prevents substrate binding by blocking the initiation of the transport cycle. The activity of progesterone as an inhibitor is attributed to its interaction with regulatory sites on ABCA8a, leading to inhibition of the protein's ATPase activity. Cyclosporine A and Glibenclamide target the ATP-binding domains, impeding the transport cycle initiation and ATP hydrolysis, which are vital for ABCA8a's function. Rifampicin selectively binds to the protein, impairing its substrate transport capabilities. Lastly, MK-571 competitively inhibits substrate binding, thereby preventing their translocation across the membrane, effectively inhibiting the function of ABCA8a. Each chemical, through its distinct mode of action, ensures that the transport activity of ABCA8a is inhibited, demonstrating the diverse ways in which small molecules can disrupt the function of this transporter protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Inhibits ABCA8a by blocking ATP-binding sites, impeding the ATPase activity necessary for substrate transport. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Inhibits the ATPase activity of ABCA8a by interacting with its ATP-binding domains, which is essential for substrate translocation. | ||||||
Elacridar | 143664-11-3 | sc-207613A sc-207613 sc-207613B sc-207613C sc-207613D | 5 mg 10 mg 50 mg 100 mg 1 g | $98.00 $113.00 $411.00 $525.00 $2606.00 | 19 | |
Inhibits ABCA8a by binding to its transmembrane domains, preventing substrate recognition and transport. | ||||||
Reserpine | 50-55-5 | sc-203370 sc-203370A | 1 g 5 g | $137.00 $414.00 | 1 | |
Prevents substrate binding to ABCA8a, thus inhibiting the initiation of the substrate transport process. | ||||||
Progesterone | 57-83-0 | sc-296138A sc-296138 sc-296138B | 1 g 5 g 50 g | $20.00 $52.00 $298.00 | 3 | |
Interacts with regulatory sites on ABCA8a, inhibiting its ATPase activity and subsequent substrate transport. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Binds to the ATP-binding domain of ABCA8a, blocking the initiation of the transport cycle and inhibiting substrate transport. | ||||||
Glyburide (Glibenclamide) | 10238-21-8 | sc-200982 sc-200982A sc-200982D sc-200982B sc-200982C | 1 g 5 g 25 g 100 g 500 g | $46.00 $61.00 $117.00 $173.00 $530.00 | 36 | |
Targets the ATP-binding domains of ABCA8a, inhibiting the ATP hydrolysis step crucial for transport activity. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Inhibits ABCA8a by selectively binding to the protein, which impairs its ability to transport substrates. | ||||||
MK-571 | 115103-85-0 | sc-201340 sc-201340A | 5 mg 25 mg | $109.00 $421.00 | 8 | |
Inhibits ABCA8a by competitively inhibiting the binding of substrates, thereby preventing their translocation across the membrane. | ||||||